Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Impact of natural menopause on multiple sclerosis: a multicentre study.

Baroncini D, Annovazzi PO, De Rossi N, Mallucci G, Torri Clerici V, Tonietti S, Mantero V, Ferrò MT, Messina MJ, Barcella V, La Mantia L, Ronzoni M, Barrilà C, Clerici R, Susani EL, Fusco ML, Chiveri L, Abate L, Ferraro O, Capra R, Colombo E, Confalonieri P, Zaffaroni M.

J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1201-1206. doi: 10.1136/jnnp-2019-320587. Epub 2019 Jun 12.

PMID:
31189614
2.

Schizophrenia and motherhood.

Gentile S, Fusco ML.

Psychiatry Clin Neurosci. 2019 Jul;73(7):376-385. doi: 10.1111/pcn.12856. Epub 2019 May 30. Review.

PMID:
31026107
3.

Structural basis of broad ebolavirus neutralization by a human survivor antibody.

West BR, Wec AZ, Moyer CL, Fusco ML, Ilinykh PA, Huang K, Wirchnianski AS, James RM, Herbert AS, Hui S, Goodwin E, Howell KA, Kailasan S, Aman MJ, Walker LM, Dye JM, Bukreyev A, Chandran K, Saphire EO.

Nat Struct Mol Biol. 2019 Mar;26(3):204-212. doi: 10.1038/s41594-019-0191-4. Epub 2019 Mar 4.

4.

Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.

Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE Jr.

J Virol. 2019 Apr 3;93(8). pii: e01439-18. doi: 10.1128/JVI.01439-18. Print 2019 Apr 15.

5.

Managing fibromyalgia syndrome in pregnancy no bridges between USA and EU.

Gentile S, Fusco ML.

Arch Womens Ment Health. 2019 Dec;22(6):711-721. doi: 10.1007/s00737-018-0933-z. Epub 2019 Jan 3. Review.

PMID:
30607517
6.

Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.

West BR, Moyer CL, King LB, Fusco ML, Milligan JC, Hui S, Saphire EO.

MBio. 2018 Sep 11;9(5). pii: e01674-18. doi: 10.1128/mBio.01674-18.

7.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

8.

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.

Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich TJ, Lai J, Chandran K, Zeitlin L, Crowe JE Jr, Lauffenburger D, Kawaoka Y, Kobinger GP, Andersen KG, Dye JM, Saphire EO, Alter G.

Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5. doi: 10.1016/j.chom.2018.07.009.

9.

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.

Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, Flinko R, Orlandi C, Carnahan R, Parrish EH, Sevy AM, Bombardi RG, Singh PK, Mukadi P, Muyembe-Tamfum JJ, Ohi MD, Saphire EO, Lewis GK, Alter G, Ward AB, Rimoin AW, Bukreyev A, Crowe JE Jr.

Immunity. 2018 Aug 21;49(2):363-374.e10. doi: 10.1016/j.immuni.2018.06.018. Epub 2018 Jul 17.

10.

Keep moving without hurting: The interaction between physical activity and pain in determining cognitive function at the population level.

Maldonato NM, Sperandeo R, Caiazzo G, Cioffi V, Cozzolino P, De Santo RM, Fusco ML, Iorio VS, Gigante E, Marone P, Nascivera N, Scognamiglio C.

PLoS One. 2018 Jun 1;13(6):e0197745. doi: 10.1371/journal.pone.0197745. eCollection 2018.

11.

Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.

Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, King H, Sapparapu G, Doranz BJ, Ksiazek TG, Wright DW, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr.

Nat Microbiol. 2018 Jun;3(6):670-677. doi: 10.1038/s41564-018-0157-z. Epub 2018 May 7.

12.

The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding.

King LB, Fusco ML, Flyak AI, Ilinykh PA, Huang K, Gunn B, Kirchdoerfer RN, Hastie KM, Sangha AK, Meiler J, Alter G, Bukreyev A, Crowe JE Jr, Saphire EO.

Cell Host Microbe. 2018 Jan 10;23(1):101-109.e4. doi: 10.1016/j.chom.2017.12.003.

13.

The Relationship Between Personality and Neurocognition Among the American Elderly: An Epidemiologic Study.

Maldonato NM, Sperandeo R, Dell'Orco S, Cozzolino P, Fusco ML, Iorio VS, Albesi D, Marone P, Nascivera N, Cipresso P.

Clin Pract Epidemiol Ment Health. 2017 Nov 28;13:233-245. doi: 10.2174/1745017901713010233. eCollection 2017.

14.

Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients.

Melcangi RC, Santi D, Spezzano R, Grimoldi M, Tabacchi T, Fusco ML, Diviccaro S, Giatti S, Carrà G, Caruso D, Simoni M, Cavaletti G.

J Steroid Biochem Mol Biol. 2017 Jul;171:229-235. doi: 10.1016/j.jsbmb.2017.04.003. Epub 2017 Apr 10.

PMID:
28408350
15.

In children 7 years of age, prenatal antidepressant exposure is not associated with increased risk of poor behavioural outcomes after adjusting for maternal factors including antenatal mood.

Gentile S, Fusco ML.

Evid Based Med. 2017 Jun;22(3):113-114. doi: 10.1136/ebmed-2016-110650. Epub 2017 Mar 27. No abstract available.

PMID:
28348049
16.

Untreated perinatal paternal depression: Effects on offspring.

Gentile S, Fusco ML.

Psychiatry Res. 2017 Jun;252:325-332. doi: 10.1016/j.psychres.2017.02.064. Epub 2017 Mar 2. Review.

PMID:
28314228
17.

Neurodevelopmental outcomes in infants exposed in utero to antipsychotics: a systematic review of published data.

Gentile S, Fusco ML.

CNS Spectr. 2017 Jun;22(3):273-281. doi: 10.1017/S1092852916000699. Epub 2016 Nov 21. Review.

PMID:
27866497
18.

Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Cross RW, Boisen ML, Millett MM, Nelson DS, Oottamasathien D, Hartnett JN, Jones AB, Goba A, Momoh M, Fullah M, Bornholdt ZA, Fusco ML, Abelson DM, Oda S, Brown BL, Pham H, Rowland MM, Agans KN, Geisbert JB, Heinrich ML, Kulakosky PC, Shaffer JG, Schieffelin JS, Kargbo B, Gbetuwa M, Gevao SM, Wilson RB, Saphire EO, Pitts KR, Khan SH, Grant DS, Geisbert TW, Branco LM, Garry RF.

J Infect Dis. 2016 Oct 15;214(suppl 3):S210-S217. Epub 2016 Aug 31.

19.

Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.

Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE Jr, Andersen KG, Saphire EO, Ward AB.

Nat Microbiol. 2016 Aug 8;1(9):16128. doi: 10.1038/nmicrobiol.2016.128.

20.

Placental and fetal effects of antenatal exposure to antidepressants or untreated maternal depression.

Gentile S, Fusco ML.

J Matern Fetal Neonatal Med. 2017 May;30(10):1189-1199. doi: 10.1080/14767058.2016.1209184. Epub 2016 Jul 21. Review.

PMID:
27379818
21.

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ.

Cell Rep. 2016 May 17;15(7):1514-1526. doi: 10.1016/j.celrep.2016.04.026. Epub 2016 May 5.

22.

Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.

Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, Sprague TR, Fusco ML, Pommert KB, Cavacini LA, Smith HL, Klempner M, Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, Ward AB, Walker LM.

Science. 2016 Mar 4;351(6277):1078-83. doi: 10.1126/science.aad5788. Epub 2016 Feb 18.

23.

Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.

Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE Jr, Chandran K, Saphire EO.

MBio. 2016 Feb 23;7(1):e02154-15. doi: 10.1128/mBio.02154-15.

24.

Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.

Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr.

Cell. 2016 Jan 28;164(3):392-405. doi: 10.1016/j.cell.2015.12.022. Epub 2016 Jan 21.

25.

Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.

Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ.

J Virol. 2015 Oct 14;90(1):266-78. doi: 10.1128/JVI.02171-15. Print 2016 Jan 1.

26.

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Oct 9;11(10):e1005212. doi: 10.1371/journal.ppat.1005212. eCollection 2015 Oct. No abstract available.

27.

Development of Prototype Filovirus Recombinant Antigen Immunoassays.

Boisen ML, Oottamasathien D, Jones AB, Millett MM, Nelson DS, Bornholdt ZA, Fusco ML, Abelson DM, Oda S, Hartnett JN, Rowland MM, Heinrich ML, Akdag M, Goba A, Momoh M, Fullah M, Baimba F, Gbakie M, Safa S, Fonnie R, Kanneh L, Cross RW, Geisbert JB, Geisbert TW, Kulakosky PC, Grant DS, Shaffer JG, Schieffelin JS, Wilson RB, Saphire EO, Branco LM, Garry RF, Khan SH, Pitts KR; Viral Hemorrhagic Fever Consortium.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S359-67. doi: 10.1093/infdis/jiv353. Epub 2015 Jul 30.

28.

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Jun 26;11(6):e1005016. doi: 10.1371/journal.ppat.1005016. eCollection 2015 Jun. Erratum in: PLoS Pathog. 2015 Oct;11(10):e1005212. Berry, Jody [corrected to Berry, Jody D].

29.

Structural basis for Marburg virus neutralization by a cross-reactive human antibody.

Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE Jr, Saphire EO.

Cell. 2015 Feb 26;160(5):904-912. doi: 10.1016/j.cell.2015.01.041.

30.

Mechanism of human antibody-mediated neutralization of Marburg virus.

Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, Crowe JE Jr.

Cell. 2015 Feb 26;160(5):893-903. doi: 10.1016/j.cell.2015.01.031.

31.

Cognitive correlates of under-ambiguity and under-risk decision making in high-functioning patients with relapsing remitting multiple sclerosis.

Cogo MG, Rota S, Fusco ML, Mapelli C, Ferri F, Appollonio IM, Isella V.

J Clin Exp Neuropsychol. 2014;36(10):1066-75. doi: 10.1080/13803395.2014.971718. Epub 2014 Dec 8.

PMID:
25486588
32.

Structures of protective antibodies reveal sites of vulnerability on Ebola virus.

Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17182-7. doi: 10.1073/pnas.1414164111. Epub 2014 Nov 17.

33.

Brain targets: can you believe your own eyes?

Stefanoni G, Tironi M, Tremolizzo L, Fusco ML, DiFrancesco JC, Patassini M, Ferrarese C, Appollonio I.

Neuroradiol J. 2014 Apr;27(2):133-7. doi: 10.15274/NRJ-2014-10025. Epub 2014 Apr 18. Erratum in: Neuroradiol J. 2014 Jun;27(3):371. Di Francesco, Jacopo [corrected to DiFrancesco, Jacopo C].

34.

Structural basis for differential neutralization of ebolaviruses.

Bale S, Dias JM, Fusco ML, Hashiguchi T, Wong AC, Liu T, Keuhne AI, Li S, Woods VL Jr, Chandran K, Dye JM, Saphire EO.

Viruses. 2012 Apr;4(4):447-70. doi: 10.3390/v4040447. Epub 2012 Apr 5. Review.

35.

Glutamate and multiple sclerosis.

Frigo M, Cogo MG, Fusco ML, Gardinetti M, Frigeni B.

Curr Med Chem. 2012;19(9):1295-9. Review.

PMID:
22304707
36.

Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.

Olal D, Kuehne AI, Bale S, Halfmann P, Hashiguchi T, Fusco ML, Lee JE, King LB, Kawaoka Y, Dye JM Jr, Saphire EO.

J Virol. 2012 Mar;86(5):2809-16. doi: 10.1128/JVI.05549-11. Epub 2011 Dec 14.

37.

A shared structural solution for neutralizing ebolaviruses.

Dias JM, Kuehne AI, Abelson DM, Bale S, Wong AC, Halfmann P, Muhammad MA, Fusco ML, Zak SE, Kang E, Kawaoka Y, Chandran K, Dye JM, Saphire EO.

Nat Struct Mol Biol. 2011 Nov 20;18(12):1424-7. doi: 10.1038/nsmb.2150.

38.

Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change.

Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM.

J Virol. 2012 Jan;86(1):364-72. doi: 10.1128/JVI.05708-11. Epub 2011 Oct 26.

39.

Generalized action myoclonus associated with escitalopram in a patient with mixed dementia.

Tremolizzo L, Fermi S, Fusco ML, Susani E, Frigo M, Piolti R, Ferrarese C, Appollonio I.

J Clin Psychopharmacol. 2011 Jun;31(3):394-5. doi: 10.1097/JCP.0b013e318218f4d5. No abstract available.

PMID:
21532372
40.

Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis.

Piazza F, DiFrancesco JC, Fusco ML, Corti D, Pirovano L, Frigeni B, Mattavelli L, Andreoni S, Frigo M, Ferrarese C, Tredici G, Cavaletti G.

J Neuroimmunol. 2010 Mar 30;220(1-2):104-7. doi: 10.1016/j.jneuroim.2010.01.011. Epub 2010 Feb 11.

PMID:
20149932
41.

Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein.

Lee JE, Fusco ML, Abelson DM, Hessell AJ, Burton DR, Saphire EO.

Acta Crystallogr D Biol Crystallogr. 2009 Nov;65(Pt 11):1162-80. doi: 10.1107/S0907444909032314. Epub 2009 Oct 22.

42.

An efficient platform for screening expression and crystallization of glycoproteins produced in human cells.

Lee JE, Fusco ML, Saphire EO.

Nat Protoc. 2009;4(4):592-604. doi: 10.1038/nprot.2009.29.

43.

Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.

Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO.

Nature. 2008 Jul 10;454(7201):177-82. doi: 10.1038/nature07082.

44.

Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.

Lee JE, Kuehne A, Abelson DM, Fusco ML, Hart MK, Saphire EO.

J Mol Biol. 2008 Jan 4;375(1):202-16. Epub 2007 Oct 16.

45.

[The psychosocial approach to the planning and implementation of vaccine trials for HIV infection].

Starace F, Embrione F, Fusco ML, Cafaro L.

Ann Ist Super Sanita. 2003;39(2):259-66. Italian.

Supplemental Content

Loading ...
Support Center